Background-Muscle wasting occurs in both chronic heart failure (CHF) and normal aging and contributes to exercise intolerance and increased morbidity/mortality. However, the molecular mechanisms of muscle atrophy in CHF and their interaction with aging are still largely unknown. We therefore measured the activation of the ubiquitin-proteasome system and the lysosomal pathway of intracellular proteolysis in muscle biopsies of CHF patients and healthy controls in two age strata and assessed the age-dependent effects of a 4-week endurance training program on the catabolic-anabolic balance.
which extent the loss of muscle mass and muscle force among elderly CHF patients is related to age or disease. We hypothesized that a sarcopenia-cachexia overlap could potentially be found in elderly CHF patients.
The Leipzig Exercise Intervention in Chronic Heart Failure and Aging (LEICA) study was therefore designed to investigate the catabolic-anabolic imbalance in the skeletal muscle associated with CHF in 2 different age strata, Յ55 years and Ն65 years, in comparison to healthy controls of the same age group. Additionally, patients and controls in each age stratum were prospectively randomized to 4 weeks of supervised endurance training or usual care to study whether age would attenuate the gains in exercise capacity and the anabolic activation in the skeletal muscle associated with cardiac rehabilitation.
In the last decade, weight loss and muscle wasting were identified as novel predictors of adverse prognosis in systolic CHF. 4 Basically, maintenance of lean muscle mass depends on an intricate balance between anabolic (growth hormone [GH] , insulin-like growth factor-I [IGF-I]) and catabolic factors (tumor necrosis factor-␣ [TNF-␣], interleukin-1␤, interferon-␥). We have shown previously in CHF that the basal expression of IGF-I is reduced, 5 whereas catabolic factors like TNF-␣, interleukin-1␤, and interleukin-6 are significantly increased. 6 On the basis of animal experiments, the most important mechanism for intracellular degradation of striated muscle proteins is the ubiquitin-proteasome system (UPS). Damaged cytosolic proteins (mutant or misfolded) and long-lived proteins such as components of the contractile apparatus of striated muscles 7 are linked to Ն4 ubiquitin molecules (ubiquitination) to be targeted toward the proteasome, where they are unfolded and cleaved into short peptides and amino acids. Three types of enzymes are involved in ubiquitination: ubiquitin-activating enzymes (E1), ubiquitinconjugating enzymes (E2), and ubiquitin ligases (E3). 8 Two E3 ligases-muscle ring finger 1 (MuRF-1) and muscle atrophy F-box (MAFbx)-were identified as being specifically expressed in striated muscle tissue and are potentially involved in CHF-related muscle wasting. 9 Proinflammatory cytokines such as TNF-␣ or interleukin-1 stimulate the expression of MuRF-1 and MAFbx, increase protein ubiquitinlation, and thereby accelerate UPS-mediated protein degradation. 9 -11 The aim of the LEICA catabolism study was specifically to analyze the role of the 2 muscle-specific atrogenes (ie, MuRF-1 and MAFbx) for the catabolic-anabolic balance in the skeletal muscle of stable CHF patients versus healthy controls in the same age stratum and their response to the anabolic stimulus of a 4-week supervised endurance training intervention in muscle biopsies of the vastus lateralis muscle before and after the intervention.
Methods

Patients
Patients with CHF and healthy controls with normal left ventricular (LV) ejection fraction in 2 age strata (Յ55 years and Ն65 years) were recruited. Patients/subjects in each of the 4 groups (healthy controls aged Յ55 years, healthy controls aged Ն65 years, CHF patients aged Յ55 years, CHF patients aged Ն65 years) were then prospectively randomized to either 4 weeks of supervised aerobic exercise training or usual care.
In regard to inclusion criteria, control subjects with normal systolic LV function (Ͼ55%) without signs or symptoms of CHF and without evidence of coronary artery disease during coronary angiography were included. CHF patients referred to the Heart Center Leipzig between June 2005 and April 2008 were enrolled on the basis of the following clinical inclusion criteria: (1) documented heart failure by signs, symptoms, and ventriculographic evidence of reduced LV function (LV ejection fraction Ͻ40%) as a result of dilated cardiomyopathy or ischemic heart disease; (2) exercise capacity at baseline Ͼ25 W; and (3) clinical stability for Ն3 months before entry into the study. To achieve a difference in mean age of Ϸ20 years between the young and old cohorts, control subjects and patients aged Յ55 years and Ն65 years were included.
Exclusion criteria were significant valvular heart disease (grade ϾII), uncontrolled hypertension, insulin-dependent diabetes mellitus, history of LV tachycardia/fibrillation without implanted cardioverter-defibrillator, peripheral vascular disease, pulmonary disease, or orthopedic comorbidities precluding exercise training.
The LEICA study research protocol was approved by the University of Leipzig Ethics Committee, and all patients provided written informed consent before entry into the study. The study was registered at http://www.clinicaltrials.gov (NCT00176319).
Training Intervention
Patients were randomly assigned to either a training group or an inactive control group by drawing a sealed envelope with intervention assignment enclosed. Four baskets of envelopes (nϭ30 each) were prepared for each of the 4 cohorts: healthy controls aged Յ55 years, healthy controls aged Ն65 years, CHF patients aged Յ55 years, and CHF patients aged Ն65 years. Cardiopulmonary exercise testing, echocardiography, skeletal muscle biopsy, and venous blood samples were obtained at baseline and after the training intervention. The exercise intervention consisted of 4 supervised training sessions per weekday for 20 minutes each (excluding 5 minutes of warming up and cooling down) with the use of a bicycle ergometer (Ergofit Inc, Pirmasens, Germany). Workloads were adjusted so that 70% of the symptom-limited maximum oxygen uptake was reached. In addition, patients and healthy controls were expected to participate in 1 group training session of 60 minutes per week. Group sessions consisted of walking, calisthenics, and ball games.
Patients assigned to the control group received usual clinical care by their physicians. All examinations including exercise testing were repeated at 4-week follow-up. Patients and healthy controls continued on their individually tailored medication. Medication included uptitrated angiotensin-converting enzyme inhibitors and ␤-blockers in all CHF patients. Patients with LV ejection fraction Ͻ30% or in New York Heart Association functional class III were maintained on stable spironolactone/eplerenone medication for a minimum of 3 months before study enrollment and throughout the study period.
Assessments
Cardiopulmonary Exercise Testing
Exercise testing was performed on a calibrated, electronically braked bicycle spiroergometry system (ZAN600, ZAN, Bad Hall, Austria) in an upright position. Workload was increased progressively every 3 minutes in steps of 25 W beginning at 25 W. Respiratory gas exchange data were determined continuously. 12 Exercise was terminated when patients were physically exhausted (as indicated by a respiratory exchange ratio Ͼ1.1) or developed severe dyspnea/ dizziness or peripheral muscle fatigue.
Echocardiography
The echocardiographic studies were performed according to current echocardiography guidelines at baseline and the end of the study by an experienced echocardiographer blinded to patient status and group assignment. Intraobserver variabilities of key parameters were Ͻ5%, and interobserver variabilities were Ͻ10%. For determination of LV ejection fraction and ventricular volumes, 3 consecutive cardiac cycles were analyzed on a GE Vivid 7 echocardiography system (software: EchoPAC Dimension '06, GE Healthcare, Chalfont St Giles, Great Britain; Simpson method of disk) and averaged for each patient.
Muscle Computed Tomography
As an established marker of skeletal muscle mass, the cross-sectional area (CSA) of the quadriceps muscle was measured by computed tomography at baseline and after 4 weeks (Siemens Somatom Plus 4, Erlangen, Germany). 13
Force Measurement
The maximal isometric force of the quadriceps muscle was measured with a dynamometer (Schnell M3 Diagnos, Peutenhausen, Germany) with a minimal resolution Ͻ1 N. The maximal voluntary isometric force was measured as an average of 5 contractions that were performed after at least 60 seconds of recovery. Force endurance was measured as the achieved time holding 50% of the maximal isometric force.
RNA Isolation and Quantification of mRNA Expression
Total RNA was isolated from frozen biopsies (RNeasy, Qiagen, Hilden, Germany) and reverse transcribed into cDNA with the use of random hexamers and Sensiscript reverse transcriptase (Qiagen, Hilden, Germany). An aliquot of the cDNA was used for quantitative real-time polymerase chain reaction (IQ5 Cycler, BioRad, Munich, Germany). Gene expression levels were normalized to the expression of 18S-rRNA. The primers/probes and conditions are detailed in Table I in the online-only Data Supplement.
Quantification of Protein Expression
Frozen tissue samples were homogenized in lysis buffer, and protein expression was quantified by Western blot with the use of specific antibodies to MuRF-1 and MAFbx (generated in rabbits by our group as described recently). After incubation with a horseradish peroxidase-conjugated secondary antibody, specific bands were visualized by enzymatic chemiluminescence (Super Signal West Pico, Pierce, Bonn, Germany). Loading differences were controlled by reprobing the blot with an antibody against GAPDH (Hytest, Turku, Finland). Ubiquitinlation was quantified with the use of a specific antibody only detecting ubiquitinylated proteins, whereas free ubiquitin is not recognized (MBL, Woburn, CA). Quantification of the protein expression was analyzed with the use of a 1-dimensional densitometric analysis software package (Scanalytics, Rockville, MD).
Measurement of Parameters of the GH/IGF-I Axis and TNF-␣
Blood samples were collected from both patients and healthy controls in the morning after a fasting period of 12 hours. GH was measured by immunofluorometric assay with the use of the Au-toDELFIA system (Wallac, Turku, Finland). Serum levels of IGF-I were measured after acid ethanol extraction by a competitive solid phase immunoassay according to the method of Kratzsch et al. 14 Serum levels of IGF binding protein 3 were determined with the use of a commercially available enzyme-linked immunosorbent assay (DSL, Sinsheim, Germany). All samples were run in duplicates, and the average value of the 2 measurements is reported. The sensitivity of the assays as well as the intra-assay and interassay coefficients of variation have been published previously. 5 All technicians were blinded for patient status (ie, study entry or finish) and assignment (ie, training or control group).
Serum concentrations of TNF-␣ were measured by a specific high-sensitivity enzyme-linked immunosorbent assay kit (Quantakine, R&D Systems, Minneapolis, MN) with a sensitivity Ͻ0.18 pg/mL. All samples were run in duplicates, and the average value of the 2 measurements is reported.
Statistical Analysis
On the basis of data from animal experiments, the change in MuRF-1 mRNA expression was used as the primary end point for the sample size calculation. A difference in treatment effect between training and control groups of 0.3 relative unit was assumed with an estimate of the SD of 0.2 relative unit. With an ␣ error of 0.05 and a ␤ error of 0.10 (power 90%), minimal group size was estimated to be 15 patients in each group.
Longitudinal data were reanalyzed by a multifactorial ANOVA with repeated measurements, with CHF, exercise, and age group as between-subject factors and time (baseline, 4 weeks) as the withinsubject factor. We starting in each case with full factorial models, and nonsignificant factors and interactions were omitted. Only significant main effects and interactions with acceptable effect size ( 2 Ͼ0.1) were reported. Additionally, comparisons within the 8 subgroups over time were analyzed by paired t test. We performed 2 tests to compare groups on categorical variables. For uncommon variables, Fisher exact test was applied. All tests were performed as 2-sided at a significance level of 0.05. Pearson linear correlation coefficient was applied to detect associations between changes in exercise capacity, force duration, and changes in MuRF-1 mRNA expression. SPSS versions 14.0 and 19.0 (IBM Germany GmbH, Munich, Germany) were used for statistical analysis. All data are presented as meanϮSEM.
Results
Baseline Characteristics and Clinical Data
From September 2005 to August 2008, a total of 60 healthy controls and 60 CHF patients were enrolled into the study. In both cohorts, 30 patients/subjects were aged Յ55 and Ն65 years, respectively ( Figure 1 ). As expected, hypertension, non-insulin-dependent diabetes mellitus, and dyslipidemia were more prevalent at baseline among elderly healthy controls than among younger healthy controls (Table 1) .
At baseline, younger and older CHF patients in the training and the control groups did not differ with respect to etiology or duration of CHF, ejection fraction, or the rate of implanted cardioverter-defibrillators. Medical therapy was similar in both groups and remained unchanged during the study period. All CHF patients were on guideline-oriented optimal medical therapy including angiotensin-converting enzyme inhibitors, ␤-blockers, aldosterone antagonists, and diuretics, as indicated ( Table 1) . As a result of the age stratification, an age difference of Ͼ20 years was observed between the 2 age strata ( Table 1) .
Within the 4 weeks of the study period, no serious adverse events, including cardiac decompensation, hospitalizations due to worsening of heart failure, revascularization procedures, acute myocardial infarction, or life-threatening ventricular arrhythmias, occurred. There were no significant changes in body weight in any study subjects.
The functional changes (on maximal aerobic exercise capacity, LV ejection fraction, and LV diameters) induced by the training intervention are described in detail in Table II in the online-only Data Supplement.
Regulation of Skeletal Muscle Protein Catabolism
Age-Related Baseline Differences
In CHF patients, both mRNA and protein expression of MuRF-1 were significantly higher compared with healthy controls ( Table 2 and Figure 2 ). However, mRNA and protein levels of MAFbx, the second muscle-specific E3 ligase, and mRNA levels of cathepsin-L were not elevated in muscle biopsies of patients with CHF versus healthy controls. 
Training Effects
Regulation of Skeletal Muscle Protein Anabolism
Age-Dependent Baseline Differences
Compared with healthy controls, CHF patients showed significantly reduced IGF-I mRNA expression in the skeletal muscle biopsies with no significant difference between younger and older patients ( Table 2 and Figure 4 ). Because of the larger standard error, no significant differences between myostatin levels in CHF patients and healthy controls were detected for each subgroup (nϭ15). However, when the baseline data for myostatin expression of all 60 CHF patients and all 60 healthy controls were pooled, a significantly higher baseline myostatin mRNA expression in muscle biopsies of CHF patients was confirmed (ϩ54.3%; 44.9Ϯ6.3 arbitrary units in CHF patients versus 29.1Ϯ3.4 arbitrary units in healthy controls; Pϭ0.03). CHF patients had significantly lower GH serum levels versus healthy controls. However, an age-related decline in GH concentrations was not detected either among healthy controls or among CHF patients ( Table 2) . Figure 4 ). In the untrained control groups and in all healthy controls, no significant change of IGF-I content could be detected. After 4 weeks of exercise training, myostatin mRNA expression remained unchanged in both patients with CHF and healthy controls ( Table 2) .
Training Effects
Muscle CSA and Muscle Function
Age-Related Baseline Differences
Compared with age-matched control subjects, the CSA of the quadriceps muscle was significantly lower among patients with CHF. Maximal force and force endurance were also significantly reduced compared with those of healthy controls. No age-related differences in muscle function were observed between the younger and the older CHF cohort ( Table 2 ). Older healthy controls had a reduced CSA compared with healthy controls aged Յ55 years. This was accompanied by a significant reduction of maximal force and force endurance among healthy controls aged Ն65 years ( Table 2) .
Training Effects
After 4 weeks of training, the quadriceps muscle CSA remained unchanged in younger and older patients of the 
Discussion
Several key messages emerge from this first prospective randomized and age-stratified clinical study to assess the effects of a supervised 4-week endurance training program on the catabolic-anabolic balance in the skeletal muscle of stable noncachectic CHF patients and control subjects, as follows:
• Catabolic activation: The mRNA and protein expression levels of the muscle-specific E3 ligase MuRF-1 were selectively upregulated in vastus lateralis biopsies of CHF patients compared with control subjects of the same age stratum. MAFbx expression remained unaffected by both the CHF disease process and age. Four weeks of endurance training significantly reduced local MuRF-1 mRNA and protein expression in the skeletal muscle of CHF patients of all ages, resulting in decreased protein ubiquitinlation. • Anabolic activation: Local expression of IGF-I mRNA was significantly reduced among CHF patients compared with healthy control subjects in the same age stratum. The present study extends previous studies in the sense that only 4 weeks of endurance training are effective in increasing local IGF-I expression in the quadriceps muscle of patients with CHF. At baseline, CHF patients showed 
Muscle Wasting and Catabolic Activation in Aging and Heart Failure
One of the strengths of the LEICA catabolism study is that muscle wasting and decline in muscle function with aging and heart failure were assessed morphometrically (by computed tomographic measurement of muscle CSA), functionally (by determination of maximal isometric force and force endurance of the quadriceps muscle), and on the molecular level. Our findings of decreased muscle CSA, force endurance, and catabolic activation in heart failure patients are consistent on all 3 levels assessed. Basically, protein degradation in eukaryotic cells can be mediated by (1) cysteine-dependent aspartate-specific proteases (caspases), 15 (2) lysosomal cathepsins, 16 (3) calciumdependent calpains, 17 and (4) the UPS. 18 -20 In recent years, the UPS has been identified as the principal regulator of muscle atrophy 19 (for an in-depth review, refer to Murton et al 21 and Foletta et al 22 ). In the LEICA study, we measured L-cathepsin to quantify the role of lysosomal protein degradation. The finding that L-cathepsin was unaffected by either CHF or the training intervention argues against a significant role of lysosomal proteolysis in CHF-associated muscle wasting.
The involvement of the UPS in human muscle wasting was documented in a number of noninflammatory (spinal cord injury, immobilization) and inflammatory conditions (cancer, sepsis, chronic obstructive pulmonary disease, amyotrophic lateral sclerosis; compare Table 2 in Reference 21). However, no data were yet available on muscle wasting in CHF. We report for the first time that the expression of the musclespecific E3 ligase MuRF-1 is significantly increased in vastus lateralis muscle biopsies from noncachectic patients with CHF, whereas MAFbx remains unaltered. This increase is not further enhanced in elderly CHF patients as may have been inferred from an animal model of sarcopenia, in which elevated MuRF-1 expression was observed in hindlimb muscles of aged rats. 23 Similarly, we did not measure any increased expression of MuRF-1 and MAFbx in elderly healthy controls without clinical evidence of sarcopenia. These observations may be explained either by the absence of any increased UPS activity without clinically manifest sarcopenia or by current concepts that the age-related loss of muscle mass is predominantly due to decreased anabolic activity caused by a resistance of skeletal muscle protein synthesis to circulating amino acids. 24 The functional relevance of the elevated MuRF-1 expression in the skeletal muscle of young and old CHF patients was confirmed by the increased level of ubiquitinlated proteins. MuRF-1 has several target proteins in skeletal myocytes, including myosin heavy chain and troponin.
The effects of long-term exercise training on MuRF-1 expression have thus far been systematically evaluated only in a 60-day bed-rest study with and without a combined endurance-resistance training program. 25 In this immobilization model for muscle atrophy, training prevented the increased protein expression of MuRF-1 in the soleus muscle and maintained fiber CSA. 25 On the other hand, bicycle ergometer training exacerbated the expression of 3 proteasome 26S subunits in a small exercise training study in 6 patients with chronic obstructive pulmonary disease. No mRNA expression measurements of muscle-specific E3 ligases were performed in the vastus lateralis biopsies. 26 In the LEICA study, a significant and consistent decrease in local skeletal muscle MuRF-1 mRNA and protein expression was observed after 4 weeks of endurance training in CHF patients. The relative decline did not differ between younger and elderly patients with CHF (Ϫ32.8% in CHF patients aged Յ55 years versus Ϫ37.0% in CHF patients aged Ն65 years). Again, MAFbx remained unchanged by the training intervention. The reduction in MuRF-1 expression was accompanied by a significant decrease in ubiquitinylated proteins. Taken together, these data confirm a significant attenuation of the elevated baseline UPS activity by endurance training in patients with stable noncachectic CHF. The findings are consistent with the concept that of the 2 skeletal muscle-specific E3 ligases, MuRF-1 is the primary regulatory factor for UPS activity and muscle atrophy in CHF.
It is well described in experimental studies that MuRF-1 and MAFbx have different substrates/binding partners in the skeletal muscle: Whereas MuRF-1 was found to bind to myosin heavy chain, titin, and troponin, 27, 28 substrates of MAFbx include MyoD and the translation initiation factor eIF3f. 29, 30 The activation pattern of muscle-specific E3 ligases observed in CHF seems to be distinct from experimental models of dexamethasone-induced muscle atrophy, in which both MuRF-1 and MAFbx were upregulated. 31 The differential regulation of MuRF-1 and MAFbx may be related to the activation of different forkhead transcription factors, as indicated by cell-line experiments. Whereas activation of MAFbx gene expression requires DNA binding of FoxO1 or FoxO3a, upregulation of MuRF-1 expression was observed independently of DNA binding of forkhead transcription factors. 32, 33 Among the healthy controls, aging was associated with a significant decrease in skeletal muscle CSA from 83Ϯ4 cm 2 /82Ϯ2 cm 2 (training and control groups, respectively) to 72Ϯ1 cm 2 /73Ϯ2 cm 2 . Such an age-dependent decline in skeletal muscle CSA was not confirmed among CHF patients, who had reduced CSA, regardless of age, between 69 and 74 cm 2 . The observation period of only 4 weeks is presumably too short to expect any significant increase in muscle CSA, which would be seen at a minimum of 8 weeks after the initiation of the training program. 34 Because of the methodology regarding patient selection (noncachectic advanced CHF patients and nonsarcopenic healthy controls), biopsy sampling from a single muscle, and the short follow-up period of 4 weeks, a number of questions remain to be answered by future studies: (1) Is there a clinical threshold (eg, related to New York Heart Association functional class or disease duration) for catabolic activation? (2) Is MuRF-1-related activation of the UPS a continuous process in advanced CHF, or do catabolic phases occur intermittently? (3) Are different types of muscle (regarding fiber type composition) affected differently by the wasting process?
Anabolic Activation
The lack of any training-induced changes in serum GH levels and the increase of local skeletal muscle IGF-I expression have been reported previously and are largely confirmatory. 5, 35 For a detailed discussion, please refer to Table III in  the online-only Data Supplement. Myostatin is a growth factor belonging to the transforming growth factor family that attenuates skeletal muscle growth. Increased myostatin mRNA expression has been reported (eg, in muscular wasting associated with glucocorticoid administration). The effects of myostatin on skeletal muscle include inhibition of protein synthesis and MyoD expression with an increase of atrogin-1 and MuRF-1 and an inhibition of Akt phosphorylation. 36 In the present study, myostatin expression in the skeletal muscle was 54.3% higher in CHF patients than in healthy controls. These data are in agreement with another recently published biopsy study from our institution in a small group of advanced CHF patients (New York Heart Association class III; nϭ24), which showed a significant increase of myostatin mRNA in skeletal muscle compared with healthy controls. 37 In these advanced stage CHF patients, prolonged exercise training over 3 months led to a 36% reduction of myostatin mRNA compared with baseline. 37 The lack of any significant reduction of myostatin expression in the LEICA study is likely to be related to the shorter training duration of only 4 weeks.
In other animal models of muscle wasting (hindlimb suspension), myostatin gene expression in the gastrocnemius was not modified. 38 Absence of myostatin expression in myostatin knockout mice did not prevent the loss of muscle mass after hindlimb suspension. On the contrary, these mice are more susceptible to unloading-induced skeletal muscle atrophy. 38 In recent animal experiments, Heineke et al 39 showed that a heart-specific deletion of myostatin with an Nkx2.5cre allele prevented skeletal muscle atrophy in heart failure. In consequence, they postulated that myocardial myostatin expression controls muscle atrophy in heart failure via elevated serum myostatin concentrations. 39 However, they used a pressure-overload model to induce heart failure, which may not be comparable to the etiology of CHF in humans. The findings of unchanged serum myostatin levels 37 and increased local myostatin mRNA expression in CHF observed in 2 independent studies may be more consistent with the relevance of local factors for the regulation of the myostatin system or indicate that serum myostatin levels may be only transiently elevated in earlier stages of CHF and therefore escape detection in stable CHF.
Clinical Results
The 4-week endurance training intervention in the LEICA study was highly effective in improving exercise capacity in both younger and older CHF patients and healthy controls. In relative terms, CHF patients increased their peak oxygen uptake by ϩ26% for those Յ55 years and by ϩ27% for those Ն65 years of age. Healthy controls improved by 24% for those Յ55 years and by ϩ19% for those Ն65 years of age. The complete lack of any attenuation of the relative training effectiveness with increasing age is a strong argument in favor of expanding rehabilitation programs into the elderly patient population. Because the molecular changes in the skeletal muscle biopsies were the primary focus of the present study, an in-depth discussion of the clinical training effects is provided in Table III in the online-only Data Supplement.
Limitations
Healthy controls aged Ͼ65 years were not entirely free from cardiovascular risk factors, which was not unexpected in a Western society. As a consequence, a number of healthy controls aged Ͼ65 years were on antihypertensive medication. However, a stable medication was required for Ն3 months, and medical therapy was kept unchanged during the entire study period. It is therefore unlikely that the study results in healthy controls were influenced by medication. Because the prevalence of diabetes mellitus was higher among CHF patients than among healthy controls and because diabetes mellitus was reported to increase UPS activation in animal models of hypoinsulinemic diabetes mellitus, there is a theoretical possibility that diabetes mellitus prevalence could increase the differences in UPS activation. However, all diabetic subjects and patients in the present study suffered from hyperinsulinemic type 2 diabetes mellitus, and no human data are available regarding the interaction between this condition and UPS activation in the skeletal muscle. Because the inclusion criteria as defined by echocardiography and clinical status were identical for both age groups, we can only compare exercise capacity and other echocardiographic or molecular parameters between different age groups with similar baseline clinical status. This is, however, fundamental for the study design, which was chosen to compare training-induced changes between different age groups of CHF patients and healthy controls. We did not seek to recruit a representative sample of all CHF patients. As a result, we did not observe an agerelated decline in exercise capacity among CHF patients, as is evident in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. 40 The present study was also not planned with the primary end point of significant gain in skeletal muscle mass. Had this been an end point, a longer training duration of Ն3 months 41 or the addition of resistance exercise interventions would have been necessary. Research in sarcopenia has long been difficult because of the lack of an internationally accepted universal definition of the disease conditions. In recent years, efforts have been made to establish a consensus definition of sarcopenia that combines anthropometric and functional criteria. 42, 43 However, clear cutoff values for muscle mass are still debated and are mainly related to the whole-body dual-energy x-ray absorptiometry scan or body impedance assessment of muscle mass. The lack of these measurements in the present study, which was planned years before any consensus definition was published, makes it difficult to use a current standard definition to exclude sarcopenia in the control cohort. However, with the use of the 2-SD criterion for muscle atrophy advocated by the Special Interest Group, 42 no older control subject had overt sarcopenia. This is corroborated by the mean VO 2 max of Ͼ20 mL/kg per minute in all elderly cohorts.
The findings of the present study do not support the initial hypothesis that age-related sarcopenia overlaps with muscle wasting in CHF patients. However, CHF patients and older control subjects included in this study did not show sarcopenia/cachexia by clinical definition at baseline despite clear evidence of muscle wasting as shown by computed tomographic scan of quadriceps CSA. It may well be that CHF patients and control subjects at more advanced ages (aged Ͼ80 years) or with more advanced heart failure need to be studied in future clinical trials to definitively prove or refute the sarcopenia-cachexia overlap hypothesis.
Areas for Future Research
It remains unknown whether the expression of MuRF-1 is permanently or temporarily elevated in systolic CHF. The finding that MuRF-1 expression remained unchanged in sedentary control CHF patients and healthy controls over the time of 4 weeks between the 2 muscle biopsies does not exclude variations in the course of CHF disease progression. To answer this question, long-term follow-up studies in CHF patients are needed, in which serial muscle biopsies are obtained at larger time intervals of several months and are correlated with changes in body mass, lean muscle mass, and exercise capacity.
Conclusions
The LEICA catabolism study is the first clinical study to specifically measure the interaction between age and disease in modulating the catabolic-anabolic balance in the skeletal muscle of CHF patients. In previous training studies in heart failure patients, elderly individuals were mostly underrepresented, making it difficult to extrapolate the beneficial effects No difference was seen between older and younger CHF patients, indicating that age did not additively contribute to ubiquitin-proteasome-mediated proteolysis in the age range studied. Four weeks of exercise training reduced MuRF-1 expression by Ϫ32.8% (Pϭ0.02) in CHF patients aged Յ55 years and by Ϫ37.0% (PϽ0.05) in CHF patients aged Ն65 years. Expression levels were decreased to the levels observed in healthy controls (HC), indicating that the training intervention effectively blocked the disease-related catabolic ubiquitin-proteasome system activation. §PϽ0.05 vs healthy controls, *PϽ0.05 vs control, #PϽ0.05 vs baseline. IGF-I indicates insulin-like growth factor-I; arb., arbitrary.
of training interventions to the age stratum in which heart failure is most prevalent.
The study documents a specific pattern of the catabolicanabolic imbalance in the skeletal muscle with reduced local IGF-I expression, increased MuRF-1, myostatin, and TNF-␣ expression, and unchanged levels of MAFbx and cathepsin-L. Four weeks of endurance training were effective in reducing the catabolic TNF-␣ and MuRF-1 expression while increas-ing IGF-I levels. Myostatin and MAFbx expression were unchanged by training.
Understanding the specific changes causing the catabolicanabolic imbalance in CHF is an essential first step in the development of pharmaceutical intervention strategies aimed at blocking muscle catabolism in CHF. For the present, endurance training provides an excellent anabolic stimulus in both younger and elderly patients with heart failure and should be regarded as a key component of an anticatabolic treatment approach in heart failure patients of all age groups.
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